Skip to content
Cultural Foundation
Author:
Crystalys Therapeutics / Russo Partners
Crystalys Therapeutics Strengthens Board of Directors and Leadership Team as Dotinurad Advances Through Global Phase 3 Development
September 23, 2026
Crystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout
July 22, 2026
Crystalys Therapeutics Doses First Patients in New Phase 2 Trial of Dotinurad for Difficult-to-Treat Gout
May 26, 2026